VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 187 filers reported holding VAXCYTE INC in Q1 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,403,651 | -0.5% | 380,613 | -2.5% | 0.23% | -1.7% |
| Q2 2023 | $19,499,373 | +108.1% | 390,456 | +56.2% | 0.23% | +81.9% |
| Q1 2023 | $9,370,000 | -21.8% | 250,000 | 0.0% | 0.13% | -20.6% |
| Q4 2022 | $11,987,500 | +154.3% | 250,000 | +27.3% | 0.16% | +142.4% |
| Q3 2022 | $4,714,000 | -53.5% | 196,429 | -57.9% | 0.07% | -57.7% |
| Q2 2022 | $10,147,000 | +337.9% | 466,324 | +378.8% | 0.16% | +372.7% |
| Q4 2021 | $2,317,000 | +218.3% | 97,396 | +323.0% | 0.03% | +13.8% |
| Q2 2020 | $728,000 | – | 23,026 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,457,300 | $54,619,604 | 23.40% |
| Pivotal bioVenture Partners Investment Advisor LLC | 693,039 | $25,975,102 | 10.70% |
| RA Capital Management | 7,291,254 | $273,276,200 | 6.19% |
| Kynam Capital Management, LP | 1,216,784 | $45,605,064 | 5.89% |
| GREAT POINT PARTNERS LLC | 659,211 | $24,707,228 | 4.85% |
| Frazier Life Sciences Management, L.P. | 1,397,405 | $52,374,739 | 3.79% |
| ACUTA CAPITAL PARTNERS, LLC | 120,500 | $4,516,340 | 3.33% |
| Ghost Tree Capital, LLC | 225,000 | $8,433,000 | 2.49% |
| Carlyle Group Inc. | 1,923,158 | $72,079,962 | 2.15% |
| Opaleye Management Inc. | 177,000 | $6,633,960 | 1.99% |